Investment Analysts’ Upgrades for November, 10th (SNDX, SPNE, STIM, TGLS, TLSNY, TOCA, TVTY, USFD, VER, VIVO)

Investment Analysts’ upgrades for Saturday, November 10th:

Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $6.25 target price on the stock. According to Zacks, “Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company’s product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. “

SeaSpine (NASDAQ:SPNE) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $20.00 target price on the stock. According to Zacks, “SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. “

Neuronetics (NASDAQ:STIM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $29.00 price target on the stock. According to Zacks, “Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. “

Tecnoglass (NASDAQ:TGLS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $10.00 target price on the stock. According to Zacks, “Tecnoglass, Inc. is engaged in manufacturing and selling architectural glass and windows and aluminum products for the residential and commercial construction industries. It operates primarily in North, Central and South America. Tecnoglass, Inc., formerly known as Andina Acquisition Corporation, is headquartered in Barranquilla, Colombia. “

TELIA Co A B/ADR (OTCMKTS:TLSNY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Telia Company AB provides network access and telecommunication services. The company also offers mobile and broadband; and fixed services, including telephony, data and TV services. It operates primarily in Sweden and Europe. Telia Company AB, formerly known as TeliaSonera AB, is headquartered in Stockholm, Sweden. “

Tocagen (NASDAQ:TOCA) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “

Tivity Health (NASDAQ:TVTY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $44.00 price target on the stock. According to Zacks, “Tivity Health, Inc. provides health management services. The company offers services which include chiropractic services, physical therapy, occupational therapy, speech therapy, acupuncture, massage and complementary and alternative medicine services. Its network comprises SilverSneakers(R), Prime(R) Fitness and WholeHealth Living (TM). Tivity Health, Inc., formerly known as Healthways, Inc., is based in Franklin, Tennessee. “

US Foods (NYSE:USFD) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “US Foods Holding Corp. is a foodservice distributor. The company serves independent and multi-unit restaurants, healthcare and hospitality entities, government and educational institutions. US Foods Holding Corp. is headquartered in Rosemont, Ill. “

Vereit (NYSE:VER) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $8.50 price target on the stock. According to Zacks, “VEREIT, Inc. is a real estate operating company. The Company owns and manages a diversified portfolio of retail, restaurant, office and industrial real estate assets. VEREIT, Inc., formerly known as American Realty Capital Properties Inc., is based in Phoenix, United States. “

Meridian Bioscience (NASDAQ:VIVO) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $23.00 target price on the stock. According to Zacks, “Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis. “

VERONA PHARMA P/S (NASDAQ:VRNA) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $14.00 price target on the stock. According to Zacks, “Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. “

Versum Materials (NYSE:VSM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Versum Materials, Inc. is an electronic materials supplier to the semiconductor industry. The company’s primary business segment consists of Materials and Delivery Systems and Services. It provides specialty process gas, cleaners and etchants, slurries, organosilanes and organometallics deposition films and equipment. Versum Materials, Inc. is headquartered in Tempe, Arizona. “

Wentworth Resource (OTCMKTS:WENTF) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Wentworth Resources Ltd. is an oil & gas company with: natural gas production; exploration and appraisal opportunities; large-scale gas monetisation initiatives primarily in the Rovuma Delta Basin of coastal southern Tanzania and northern Mozambique. Wentworth Resources Ltd. is headquartered in Calgary, Canada. “

Exela Technologies (NASDAQ:XELA) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Exela Technologies, Inc. is engaged in providing information and transaction processing solutions. The Company’s segments include Information and Transaction Processing Solutions, Healthcare Solutions and Legal & Loss Prevention Services. ITPS provides industry solutions for banking and financial services, including lending solutions for mortgages, banking solutions for clearing, anti-money laundering, sanctions, cross-border settlement; property and casualty insurance solutions for enrollments, and communications. The HS segment offerings include integrated accounts payable and accounts receivable, and information management for both the healthcare payer and provider markets. The LLPS segment solutions include processing of legal claims for class action and mass action settlement administrations, involving project management support, notification and collection, analysis, and distribution of settlement funds. Exela Technologies Inc., formerly known as Quinpario Acquisition Corp. 2, is based in United States. “

Receive News & Ratings for Syndax Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply